How Did Madrigal Pharmaceuticals Turn a $114 Million Loss Into a Q3 Profit as Rezdiffra Sales Surpassed $1 Billion?
Madrigal Pharmaceuticals (MDGL) reported Q3 2026 profit of $55.4M, reversing a $114.2M loss from 2025, driven by 50% revenue growth to $431.3M. Rezdiffra sales surpassed $1B year-to-date, achieving blockbuster status. The company plans new trials for expanded use in cirrhosis patients. CEO Bill Sibold cited strong demand and market growth.
How this was made
The 30-second read
Why it matters
The quarter’s return to profitability, the $1B YTD sales milestone, and the announcement of a new Phase 3 outcomes trial (MAESTRO-CSPH) provide multiple catalysts that can re-rate near-term fundamentals and extend the growth runway into label expansion.
Market read
Traders may adjust MDGL positioning ahead of the AASLD meeting and in anticipation of continued Rezdiffra adoption, while monitoring execution risk for the next Phase 3 outcomes program.
What to watch
The article highlights planned Phase 3 expansion but does not provide interim efficacy/safety readouts for F4c or CSPH; trial outcomes and regulatory interpretation remain key swing factors.
Background
Madrigal’s Rezdiffra (resmetirom) is an approved treatment for MASH with moderate to advanced liver fibrosis (F2-F3), and the company is expanding into more advanced compensated cirrhosis (F4c).
Ticker impact
Madrigal reported Q3 2026 profitability, with net income of $55.4M and Rezdiffra net sales surpassing $1B YTD, plus plans for new Phase 3 trials.
Likely upward bias as traders price in sustained Rezdiffra growth and higher probability of label expansion from upcoming Phase 3 outcomes.
The article discloses fresh quarterly financial results, a $1B YTD sales milestone, and concrete next-step trial plans (MAESTRO-CSPH initiation in H1 2027, plus Phase 3 for F4c), which together can shift near-term fundamentals and longer-dated growth expectations.
Market effects
Strength in a leading MASH franchise can support sentiment across liver-disease and metabolic-inflammation biotech peers, especially those with late-stage programs.
Primarily US biotech sentiment, with potential spillover to European pharma investors tracking MASH adoption given Rezdiffra’s EU approval context.
Rezdiffra’s rapid blockbuster trajectory and expanding trial roadmap can influence global expectations for the MASH treatment market growth curve.
Counterpoint
Profitability could be more dependent on near-term commercial execution and expense control than durable long-term demand, so the market may over-extrapolate the current momentum.
Key entities
- companyMadrigal Pharmaceuticals
Reported Q3 2026 profitability, highlighted Rezdiffra demand, and outlined additional Phase 3 development for advanced compensated MASH cirrhosis.
- productRezdiffra (resmetirom)
Madrigal’s MASH therapy that surpassed $1B in year-to-date net sales and is being studied for broader patient populations.
- clinical_trialMAESTRO-CSPH
Planned Phase 3 event-driven outcomes trial for well-compensated MASH cirrhosis enriched for clinically significant portal hypertension, expected to start in H1 2027.
- clinical_trialMAESTRO-NASH OUTCOMES
Ongoing Phase 3 outcomes study evaluating Rezdiffra in compensated MASH cirrhosis (F4c).
- eventAASLD Liver Meeting (Nov 5-9, 2026)
Conference where Madrigal plans to present extensive real-world and clinical evidence for resmetirom.
